Drug for auditory dysfunction
AssigneeAnGes MG, Inc.
InventorsYasufumi Kaneda, Kazuo Oshima, Ryuichi Morishita, Takeshi Kubo
Life of this patent
Estimating the term…
Abstract
The present invention provides a pharmaceutical preparation for hearing impairment, which is suitable for gene therapy of hearing impairment, that is, a pharmaceutical preparation for hearing impairment which comprises a virus envelope vector encapsulating a hepatocyte growth factor (HGF) gene or its plasmid as an active ingredient. Particularly, it is suitable as a pharmaceutical preparation for gene therapy for the purpose of prevention and treatment of deafness.
Claims9
A pharmaceutical preparation for hearing impairment, which comprises a hepatocyte growth factor (HGF) gene as an active ingredient.
A pharmaceutical preparation for hearing impairment, which comprises a plasmid of a hepatocyte growth factor (HGF) gene as an active ingredient.
A pharmaceutical preparation for hearing impairment, which comprises a virus envelope vector encapsulating a hepatocyte growth factor (HGF) gene or its plasmid as an active ingredient.
Use of a hepatocyte growth factor (HGF) gene or a plasmid of a hepatocyte growth factor (HGF) gene for producing a pharmaceutical preparation for hearing impairment.
A method of treating hearing impairment, which comprises administering, to a patient with hearing impairment, a hepatocyte growth factor (HGF) gene or a plasmid of a hepatocyte growth factor (HGF) gene in an amount effective for the treatment.
Dependencies are inferred from the claim text.